COMP <GO>
JAZZ vs ABBV // FORWARD P/E MULTIPLE
Jazz Pharmaceuticals plc Common Stock (Ireland) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: JAZZ 3
— ABBV 10
▲ FORWARD P/E MULTIPLE LEADER: JAZZ
LAST: $215.98 (+3.92%) • MKT CAP: $13.49B
forward-pe
36.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAZZ VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JAZZ | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.70% | 29.00% | -33.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 9.61% | 3.47% | +6.14 | JAZZ | /fcf-yield <GO> |
| Operating Margin | -10.10% | 24.60% | -34.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.30% | 6.90% | -15.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.90% | 8.60% | -3.70 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.97 | 5.33 | -3.36 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | JAZZ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.4 | 72.8 | -26.40 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.15 | -0.06 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 36.0x | 113.1x | -77.10 | JAZZ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.49B | $513.86B | -$500.37B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JAZZ REV | ABBV REV | JAZZ GROSS % | ABBV GROSS % | JAZZ FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | $61.16B | 44.0% | 70.2% | $1.30B | $17.82B |
| FY 2024 | $4.07B | $56.33B | 44.0% | 70.0% | $1.36B | $17.83B |
| FY 2023 | $3.83B | $54.32B | 44.0% | 44.0% | $919.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAZZ // BETA 1.09
ABBV // BETA 1.15